BALA CYNWYD, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Kenvue Inc. (NYSE - KVUE)

Under the terms of the agreement, Kenvue will be acquired by Kimberly-Clark Corporation (Nasdaq - KMB). Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly-Clark shares for each Kenvue share held at closing, for total consideration to Kenvue shareholders of $21.01 per share, based on the closing price of Kimberly-Clark shares as of October 31, 2025. The investigation concerns whether the Kenvue Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/kenvue-inc-nyse-kvue .

Sonida Senior Living, Inc. (NYSE - SNDA)

Under the terms of the Merger Agreement, Sonida Senior Living will be acquired by CNL Healthcare Properties, Inc. (“CHP”) for $6.90 per share of CHP, with approximately 66% of the consideration expected to be in the form of newly issued Sonida common stock and 34% in cash. The investigation concerns whether the Sonida Senior Living Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/sonida-senior-living-inc-nyse-snda/.

Evoke Pharma Inc. (Nasdaq - EVOK)

Under the terms of the Merger Agreement, Evoke Pharma will be acquired by QOL Medical for $11.00 per share in cash at closing. The investigation concerns whether the Evoke Pharma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/evoke-pharma-inc-nasdaq-evok/.

SM Energy Company (NYSE - SM)

Under the terms of the Merger Agreement, SM Energy will be acquired by Civitas Resources, Inc. (“Civitas”) (NYSE - CIVI). Each common share of Civitas will be exchanged for 1.45 shares of SM Energy common stock. The combined company's enterprise value of approximately $12.8 billion is inclusive of each company's net debt. The investigation concerns whether the SM Energy Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/sm-energy-company-nyse-sm/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.